Research on the tumor microenvironment, including immune, stromal, vascular, and extracellular matrix interactions
Latest Research Highlights
From November 2025
TAMs expressing TREM2 are key immunosuppressive cells, highlighting the need for multi-modal immunotherapy strategies (ref: von Locquenghien doi.org/10.1016/j.cell.2025.10.030/)
IL-9 signaling enhances CAR T cell efficacy in solid tumors by promoting expansion and persistence (ref: Castelli doi.org/10.1016/j.immuni.2025.10.021/)
Cellular senescence can transition from tumor suppression to promoting a pro-tumoral microenvironment (ref: Hoi doi.org/10.1016/j.ccell.2025.10.006/)
Inflammatory cytokines like IL-6 contribute to chemoresistance in NSCLC, with potential for therapeutic targeting (ref: Dai doi.org/10.5306/wjco.v16.i10.112097/)
The combination of sitravatinib and tislelizumab shows promising efficacy in advanced biliary tract cancer (ref: Yoon doi.org/10.1016/j.jhep.2025.10.032/)
Oligomeric cystatin C supports immunosuppressive myeloid cell activity, indicating a role for amyloid proteins in cancer (ref: Zhang doi.org/10.1038/s41392-025-02462-x/)
Targeting maladaptive myelopoiesis in the bone marrow can reverse macrophage-mediated immunosuppression in cancer (ref: Jin doi.org/10.1016/j.immuni.2025.10.015/)